Details of the role of the new supplement in providing support for canine cardiac disorder: ...

Patent Covers Invention of Treatment Drug and Prophylactic Drug for Lowering Cardiac Disorder Markers in Dogs as ...

BACKGROUND: Patients with hypertrophic cardiomyopathy without left ventricular outflow tract obstruction commonly experience ...

Scarecrow Incorporated, a manufacturer engaging in the research, development, and distribution of supplements for animals, has obtained the world's first patent for Pinfenon (S), a product the company ...

Aristotle Atlantic Partners, LLC, an investment advisor, released its “Large Cap Growth Strategy” third quarter 2024 investor ...

When patients were re-classified based on the adjusted thresholds of N-terminal pro-brain natriuretic peptide and 6-minute walk distance and the inclusion of TAPSE rather than right atria area, ...

Updated guidelines on allogeneic hematopoietic stem cell transplantation for myelofibrosis examine spleen-related ...

The latter enzyme is responsible for the breakdown of the three natriuretic peptides -- atrial natriuretic peptide, brain-derived natriuretic peptide, and C-type natriuretic peptide -- and bradykinin.

Background Previous research has suggested a heightened risk of acute myocarditis after COVID-19 infection. However, it is ...

Risk for heart failure events is decreased and health status is improved in patients with HFmrEF and HFpEF receiving finerenone.

A study has found that aficamten is associated with improvements across a range of clinical outcomes in patients with obstructive hypertrophic cardiomyopathy.